Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Indole-3 Propionic Acid Deficiency and Gut Microbiota Imbalance in Follicular Lymphoma: Implications for Disease Progression and Therapeutic Potential

Li Zhang, Bintao Xie, Jiakuan Zhou, Han Lin, Haiyang Lu, Jun Meng, Jianbiao Wang, Pengpeng Xu, Lina Zhang, Xiaohua Chen, Xiaohui Zhou, Hao Liu

Blood (2024) 144 (Supplement 1): 6252.

https://doi.org/10.1182/blood-2024-205708

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Yuqing Wang, Shuo Wang, Hongmei Yi, Yue Wang, Haimin Xu, Shuang Tian, Yan Dong, Jing Zhao, Di Fu, Rongji Mu, Shuye Wang, Li Wang, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2024-202864

Published: 2024

Journal Articles

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Yue Wang, Xue Wang, Xinyun Huang, Ying Qian, Rongji Mu, Qing Shi, Di Fu, Hongmei Yi, Bin-Shen Ou-Yang, Zhuo Han Li, Shu Cheng, Wang Li, Ning Wen, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2024-206537

Published: 2024

Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao

Blood (2024) 144 (Supplement 1): 6553.

https://doi.org/10.1182/blood-2024-203842

Published: 2024

Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4502.3.

https://doi.org/10.1182/blood-2024-204749

Published: 2024

Journal Articles

The Impact of Gut Microbiota Diversity on Follicular Lymphoma: Insights into Disease Progression and Therapy

Li Zhang, Bintao Xie, Jiakuan Zhou, Han Lin, Jun Meng, Jianbiao Wang, Haiyang Lu, Lina Zhang, Xiaohua Chen, Xiaohui Zhou, Hao Liu, Pengpeng Xu

Blood (2024) 144 (Supplement 1): 6275.

https://doi.org/10.1182/blood-2024-205472

Published: 2024

Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao

Blood (2024) 144 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2024-204775

Published: 2024

Journal Articles

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Yige Shen, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2023-188042

Published: 2023

Journal Articles

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Wang Li, Shu Cheng, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2023-186087

Published: 2023

Journal Articles

Selinexor in Combination with Salvage Regimen for Refractory Peripheral T-Cell Lymphoma (PTCL) Patients

Li Wang, Mingci CAI, Yaohui Huang, Pengpeng Xu, Shu Chen, Weili Zhao

Blood (2023) 142 (Supplement 1): 6211.

https://doi.org/10.1182/blood-2023-183040

Published: 2023

Journal Articles

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Yige Shen, Yiwen Cao, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 3091.

https://doi.org/10.1182/blood-2023-182603

Published: 2023

Journal Articles

Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Li Wang, Ying Fang, Muchen Zhang, Jie Xiong, Pengpeng Xu, Shu Chen, Weili Zhao

Blood (2023) 142 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2023-182674

Published: 2023

Journal Articles

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naïve Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma

Pengpeng Xu, Ni Fan, Yamin Tian, Xinran Tang, Bin Zhang, Wei Zhou, Renbin Zhao, Weili Zhao

Blood (2022) 140 (Supplement 1): 12110.

https://doi.org/10.1182/blood-2022-158865

Published: 2022

Journal Articles

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Li Wang, Shu Cheng, Wei Li Zhao

Blood (2021) 138 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2021-146851

Published: 2021

Journal Articles

Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+ Lymphoma in China

Pengpeng Xu, Mingci Cai, Wendy Zhang, Wei Li Zhao

Blood (2021) 138 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2021-149031

Published: 2021

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 4083.

https://doi.org/10.1182/blood-2019-126408

Published: 2019

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

NARROW

Indole-3 Propionic Acid Deficiency and Gut Microbiota Imbalance in Follicular Lymphoma: Implications for Disease Progression and Therapeutic Potential

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

The Impact of Gut Microbiota Diversity on Follicular Lymphoma: Insights into Disease Progression and Therapy

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Selinexor in Combination with Salvage Regimen for Refractory Peripheral T-Cell Lymphoma (PTCL) Patients

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naïve Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+ Lymphoma in China

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only